QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momen

Bond yields have the entire stock market on edge. The last thing most investors are thinking about i

On Wednesday, uniQure N.V. (NASDAQ:QURE) submitted its Biologics License Application (BLA) to the U.

uniQure seeks accelerated FDA approval for its Huntington's gene therapy, AMT-130. William Blair

Dutch gene therapy developer uniQure said on Wednesday it had applied for U.S. approval of its exper

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for pa

~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene i

uniQure (QURE) reported earnings 30 days ago. What's next for the stock?

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130

Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the pr

Wolfe Research analyst Rudy Li upgrades uniQure (NASDAQ:QURE) from Peer Perform to Outperform and

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise

Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the pr

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential a

uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate

uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consen

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for

~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earn

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business

QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulat

QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and c

uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy an

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

Mizuho analyst Uy Ear maintains uniQure (NASDAQ:QURE) with a Outperform and raises the price targ

LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal w

uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related se

FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap

Barclays analyst Eliana Merle upgrades uniQure (NASDAQ:QURE) from Equal-Weight to Overweight and

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and raises t

Leerink Partners analyst Joseph Schwartz maintains uniQure (NASDAQ:QURE) with a Outperform and ra

RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and raises the pr

U.S. stocks up, Dow Jones gains 0.39%. NASDAQ rose 0.09%, S&P 500 up 0.11%. Industrials shares j

uniQure stock surged after the FDA said three-year AMT-130 data could support accelerated approval f

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Ap

https://endpoints.news/acting-fda-commissioner-pledges-to-prevent-political-interference-in-rare-dis

US stocks up, Dow Jones up 171 pts. Replimune Group rises after FDA agreement. Other big gainers inc